Article
Substance Abuse
Lara N. Coughlin, Mark A. Ilgen, Mary Jannausch, Maureen A. Walton, Kipling M. Bohnert
Summary: Research shows that individuals using medical cannabis to manage chronic pain may experience mild to severe withdrawal symptoms, with these symptoms tending to be stable over a 2-year period. Younger age is associated with greater severity and worsening of withdrawal symptoms over time.
Review
Clinical Neurology
Hayley H. A. Thorpe, M. Asfandyaar Talhat, Jibran Y. Khokhar
Summary: Cannabis use has a substantial heritable component, with different gene variants potentially contributing to various stages of use. Understanding genetic risk factors in cannabis use can provide insights into biological mechanisms and aid in intervention and drug development for treating problematic use.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Biochemistry & Molecular Biology
Margaret Haney, Monique Vallee, Sandy Fabre, Stephanie Collins Reed, Marion Zanese, Ghislaine Campistron, Caroline A. Arout, Richard W. Foltin, Ziva D. Cooper, Tonisha Kearney-Ramos, Mathilde Metna, Zuzana Justinova, Charles Schindler, Etienne Hebert-Chatelain, Luigi Bellocchio, Adeline Cathala, Andrea Bari, Roman Serrat, David B. Finlay, Filippo Caraci, Bastien Redon, Elena Martin-Garcia, Arnau Busquets-Garcia, Isabelle Matias, Frances R. Levin, Francois-Xavier Felpin, Nicolas Simon, Daniela Cota, Umberto Spampinato, Rafael Maldonado, Yavin Shaham, Michelle Glass, Lars Lykke Thomsen, Helle Mengel, Giovanni Marsicano, Stephanie Monlezun, Jean-Michel Revest, Pier Vincenzo Piazza
Summary: Cannabis use disorder (CUD) is a widespread problem with no current pharmacological treatment options. AEF0117, a signaling-specific inhibitor of the cannabinoid receptor 1, has shown promise in reducing self-administration of cannabis and THC-related behavioral impairment without significant adverse effects in animal studies. Clinical trials involving healthy volunteers and individuals with CUD found that AEF0117 was safe, well tolerated, and significantly reduced the positive subjective effects of cannabis.
Article
Psychology, Clinical
Scott Graupensperger, Anne M. Fairlie, Jason J. Ramirez, Brian H. Calhoun, Megan E. Patrick, Christine M. Lee
Summary: This study examines the effects of sleep duration on next-day alcohol and cannabis craving and use among young adults. The results suggest that shorter sleep duration is associated with stronger craving for alcohol and cannabis, as well as higher alcohol use.
ADDICTIVE BEHAVIORS
(2022)
Review
Biochemistry & Molecular Biology
Andrew J. Kesner, David M. Lovinger
Summary: Cannabis sativa is the most widely used illicit drug in the world, with its main psychoactive component being THC. Despite its medical therapeutic qualities, frequent cannabis or THC users may develop cannabis use disorder, exhibiting classical addiction symptoms. Effective treatments for cannabis use disorder and withdrawal symptoms are currently lacking, highlighting the importance of research on the neurobiological mechanisms underlying these syndromes.
JOURNAL OF NEUROCHEMISTRY
(2021)
Article
Medicine, General & Internal
Sarah C. M. Roberts, Claudia Zaugg, M. Antonia Biggs
Summary: A cross-sectional study found that warning signs policies mandating point-of-sale warnings about the risks of cannabis use during pregnancy did not reduce cannabis use during pregnancy. However, these policies were associated with increased support for punishment and stigma among those who did not use cannabis.
Article
Psychology, Clinical
Michael J. Zvolensky, Brooke Y. Kauffman, Lorra Garey, Julia D. Buckner
Summary: This study found an association between abstinence phobia and more severe cannabis use problems, perceived barriers for quitting cannabis use, and more severe withdrawal symptoms among African American/Black individuals. This suggests that abstinence phobia may be an underrecognized intervention target for addressing cannabis use problems and promoting successful quit attempts.
ADDICTIVE BEHAVIORS
(2022)
Editorial Material
Biochemistry & Molecular Biology
Thomas P. Sakmar
Summary: This study reveals that the increased cardiovascular risks associated with cannabis use are caused by proinflammatory signaling of the cannabinoid 1 (CB1) receptor, which can be alleviated by the natural antioxidant genistein.
Article
Substance Abuse
Elif Merve Kurt Tunagur, Ahmet Bulent Yazici, Derya Guzel, Mustafa Tolga Tunagur, Cagatay Ermis, Mehmet Akif Suda, Esra Yazici
Summary: This study investigated the association between appetite-regulating hormones, aggression, and craving during cannabis withdrawal syndrome (CWS). The results showed that patients with CWS had lower levels of ghrelin and adiponectin compared to controls at baseline, but had a significant increase in ghrelin levels after PSAP. Furthermore, there was a positive association between craving and resistin levels.
DRUG AND ALCOHOL DEPENDENCE
(2022)
Article
Public, Environmental & Occupational Health
Jennifer A. Bailey, Stacey S. Tiberio, David C. R. Kerr, Marina Epstein, Kimberly L. Henry, Deborah M. Capaldi
Summary: Canada, Uruguay, and 18 states in the U.S. have legalized nonmedical cannabis for adults, but the impact on adolescent cannabis use remains unclear. This study found that cannabis legalization did not predict changes in adolescent cannabis use among 13-18 year olds in Oregon, New York, and Washington. Findings suggest that legalization did not affect the prevalence or frequency of adolescent cannabis use.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2023)
Article
Medicine, General & Internal
Gwen T. Lapham, Theresa E. Matson, Jennifer F. Bobb, Casey Luce, Malia M. Oliver, Leah K. Hamilton, Katharine A. Bradley
Summary: The prevalence and severity of cannabis use disorders (CUD) among primary care patients in a state with legal recreational use were examined. The study found that CUD was common among cannabis users, with higher rates observed among those who reported nonmedical use. These findings highlight the importance of assessing cannabis use and CUD symptoms in medical settings.
Article
Multidisciplinary Sciences
Carrie Cuttler, Emily M. LaFrance, Amanda Stueber
Summary: Statewide legislation has increased access to high-potency cannabis, but federal restrictions limit access to research on low-potency whole-plant cannabis. This study examined the acute cognitive effects of high-potency cannabis, finding that high-potency flower with CBD impaired free recall, flower without CBD and concentrates affected source memory, and all three products increased susceptibility to false memories.
SCIENTIFIC REPORTS
(2021)
Article
Psychology, Clinical
Pablo Romero-Sanchiz, Ioan T. Mahu, Sean P. Barrett, Joshua P. Salmon, Mohammed Al-Hamdani, Jennifer E. Swansburg, Sherry H. Stewart
Summary: Conditioned craving to trauma cues and avoidance learning are factors in comorbid trauma-related distress and substance misuse. Exposure to trauma cues may increase cannabis misuse through conditioned craving and the desire to relieve negative emotions, especially in individuals with more severe PTSD symptoms.
ADDICTIVE BEHAVIORS
(2022)
Article
Public, Environmental & Occupational Health
Jason R. Kilmer, Isaac C. Rhew, Katarina Guttmannova, Charles B. Fleming, Brittney A. Hultgren, Michael S. Gilson, Rachel L. Cooper, Julia Dilley, Mary E. Larimer
Summary: Prevalence of cannabis use and cannabis use disorder symptomatology among young adults in Washington State has increased since legalization, especially among those of legal age. This trend requires ongoing monitoring.
AMERICAN JOURNAL OF PUBLIC HEALTH
(2022)
Article
Medicine, General & Internal
Amanda Doggett, Kyla Belisario, Andre J. Mcdonald, Mark A. Ferro, James G. Murphy, James Mackillop
Summary: A longitudinal observational cohort study in Canada found that there were decreases in cannabis use frequency and related consequences among high-risk young adults after recreational cannabis legalization.
Article
Biochemistry & Molecular Biology
Joseph P. Schacht, Raymond F. Anton, Patrick J. McNamara, Yeongbin Im, Andrea C. King
Article
Substance Abuse
James J. Prisciandaro, Joseph P. Schacht, Andrew P. Prescot, Perry F. Renshaw, Truman R. Brown, Raymond F. Anton
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
(2019)
Article
Psychology, Clinical
Hollis C. Karoly, Joseph P. Schacht, Lindsay R. Meredith, Joanna Jacobus, Susan F. Tapert, Kevin M. Gray, Lindsay M. Squeglia
ADDICTIVE BEHAVIORS
(2019)
Article
Substance Abuse
Hollis C. Karoly, Joseph P. Schacht, Joanna Jacobus, Lindsay R. Meredith, Charles T. Taylor, Susan F. Tapert, Kevin M. Gray, Lindsay M. Squeglia
DRUG AND ALCOHOL DEPENDENCE
(2019)
Article
Biochemistry & Molecular Biology
James J. Prisciandaro, Joseph P. Schacht, Andrew P. Prescot, Helena M. Brenner, Perry F. Renshaw, Truman R. Brown, Raymond F. Anton
Review
Substance Abuse
Emily E. Hartwell, Richard Feinn, Paige E. Morris, Joel Gelernter, John Krystal, Albert J. Arias, Michaela Hoffman, Ismene Petrakis, Ralitza Gueorguieva, Joseph P. Schacht, David Oslin, Raymond F. Anton, Henry R. Kranzler
Article
Substance Abuse
Raymond F. Anton, Konstantin E. Voronin, Sarah W. Book, Patricia K. Latham, Patrick K. Randall, Willam Bailey Glen, Michaela Hoffman, Joseph P. Schacht
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
(2020)
Article
Substance Abuse
Elizabeth M. Burnette, Erica N. Grodin, Joseph P. Schacht, Lara A. Ray
Summary: The study found differences between reward and relief/habit-motivated drinking behaviors, with relief/habit drinkers exhibiting higher AUD severity on clinical measures and greater activation in the dorsal striatum in response to controlled alcohol cues. These findings contribute to a better understanding of drinking behavior categorization and treatment for AUD.
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH
(2021)
Editorial Material
Anesthesiology
Karsten Bartels, Joseph P. Schacht
ANESTHESIA AND ANALGESIA
(2021)
Article
Genetics & Heredity
Joseph P. Schacht, Michaela Hoffman, Brian H. Chen, Raymond F. Anton
Summary: The study found that methylation levels in OPRM1, SLC6A3, and COMT genes were associated with the efficacy of naltrexone in treating heavy drinking in individuals with AUD, with lower methylation levels leading to fewer heavy drinking days. This suggests that epigenetic modification of these genes could be a novel predictor of naltrexone efficacy in AUD treatment.
PHARMACOGENOMICS JOURNAL
(2022)
Article
Biochemical Research Methods
Hamed Ekhtiari, Mehran Zare-Bidoky, Arshiya Sangchooli, Amy C. Janes, Marc J. Kaufman, Jason A. Oliver, James J. Prisciandaro, Torsten Wustenberg, Raymond F. Anton, Patrick Bach, Alex Baldacchino, Anne Beck, James M. Bjork, Judson Brewer, Anna Rose Childress, Eric D. Claus, Kelly E. Courtney, Mohsen Ebrahimi, Francesca M. Filbey, Dara G. Ghahremani, Peyman Ghobadi Azbari, Rita Z. Goldstein, Anna E. Goudriaan, Erica N. Grodin, J. Paul Hamilton, Colleen A. Hanlon, Peyman Hassani-Abharian, Andreas Heinz, Jane E. Joseph, Falk Kiefer, Arash Khojasteh Zonoozi, Hedy Kober, Rayus Kuplicki, Qiang Li, Edythe D. London, Joseph McClernon, Hamid R. Noori, Max M. Owens, Martin Paulus, Irene Perini, Marc Potenza, Stephane Potvin, Lara Ray, Joseph P. Schacht, Dongju Seo, Rajita Sinha, Michael N. Smolka, Rainer Spanagel, Vaughn R. Steele, Elliot A. Stein, Sabine Steins-Loeber, Susan F. Tapert, Antonio Verdejo-Garcia, Sabine Vollstaedt-Klein, Reagan R. Wetherill, Stephen J. Wilson, Katie Witkiewitz, Kai Yuan, Xiaochu Zhang, Anna Zilverstand
Summary: This study established parameters and reporting standards for cue reactivity research in functional magnetic resonance imaging, and conducted a review on relevant published studies, revealing gaps in the reporting of important items.
Article
Neurosciences
Joseph P. Schacht, Yeongbin Im, Michaela Hoffman, Konstantin E. Voronin, Sarah W. Book, Raymond F. Anton
Summary: This study suggests that the COMT inhibitor tolcapone may only be effective in reducing alcohol consumption among individuals who are genetically predisposed to excessive COMT activity and potentially have low cortical dopamine levels.
NEUROPSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Jarrod M. Ellingson, Jesse D. Hinckley, J. Megan Ross, Joseph P. Schacht, L. Cinnamon Bidwell, Angela D. Bryan, Christian J. Hopfer, Paula Riggs, Kent E. Hutchison
Summary: Research suggests that cannabis use may be associated with poorer neurocognitive functioning, especially in adolescence, but some studies have not found clear evidence of impairment. The endocannabinoid system may play a role in how cannabis affects neurocognitive functions, potentially offering protective effects in older adults.
CURRENT BEHAVIORAL NEUROSCIENCE REPORTS
(2021)
Meeting Abstract
Substance Abuse
J. P. Schacht, M. Hoffman, K. E. Voronin, R. F. Anton
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
(2019)
Meeting Abstract
Substance Abuse
M. Hoffman, Z. Adams, J. Schacht, K. Voronin, P. Latham, E. Bristol, R. Anton
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
(2019)